Plain-English translation of NCT06607120 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying patients with advanced liver cancer who are receiving a combination of three treatments: a minimally invasive procedure called transarterial chemoembolization (TACE), immune checkpoint inhibitors (which help your immune system fight cancer), and anti-angiogenesis drugs (which cut off blood supply to tumors). The goal is to create a personalized prediction model that identifies which patients will respond best to this combination approach, so doctors can make better treatment decisions in the future.
Previous research shows that combining these three treatments works better than using immune and targeted drugs alone for advanced liver cancer. However, doctors currently lack a reliable way to predict which patients will benefit the most from this combination, leaving uncertainty about who should receive it.
You likely qualify if…
You likely don't qualify if…
This is primarily an observational study, meaning you will not receive experimental treatment—instead, researchers will collect and analyze information from your existing medical records, treatment history, and imaging scans. Your participation involves sharing your clinical data and allowing the research team to track how well the combination treatment works for you over time, with the goal of building a model that helps future patients like you.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
Zhongda Hospital
Enrollment target
~950 participants
Started
June 2024
Primary completion
January 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gao-Jun Teng, M.D
Zhongda hospital, Southeast university, Nanjing, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.